small molecule

EZETIMIBE AND SIMVASTATIN

EZETIMIBE; SIMVASTATIN

Loss of exclusivity—loss of exclusivity
CompanyAmneal Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameEZETIMIBE AND SIMVASTATIN
Active ingredientEZETIMIBE; SIMVASTATIN
Strength10MG;40MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2017
Marketing statusDISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.